Reduce tremor slowness and stiffness
- Trial ID
- NCT07348705
- Official Title
- Electrophysiology-based Deep Brain Stimulation Programming for Parkinson's Disease
- Goal
- Reduce tremor slowness and stiffness
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- University of Florida
- Study Type
- INTERVENTIONAL
- Enrollment
- 30 participants
- Conditions
- Parkinson's Disease (PD)
- Interventions
- Clinician-based DBS programming, Maximum Beta power-based DBS programming, Broad-band electrophysiology-based DBS programming
Plain-Language Summary
The team wants to know if using the brain's own electrical signals to guide deep brain stimulation can give more precise, faster relief of motor symptoms like tremor, slowness, and stiffness than usual clinician-led programming. Using the Medtronic Percept DBS, the study compares standard clinician programming to two signal-guided methods, one that sets stimulation where beta-band power is highest and one that uses broader electrophysiology patterns, with the goal of reducing abnormal brain oscillations while patients continue their regular medications. Adults 21 to 89 with idiopathic Parkinson’s who already have a Percept DBS implanted and can consent at their initial programming session are eligible; people with atypical parkinsonism or who cannot follow the protocol are excluded.
Locations
- Norman Fixel Institute for Neurological Diseases, Gainesville, Florida, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Clinician-based DBS programming. The team wants to know if using the brain's own electrical signals to guide deep brain stimulation can give more precise, faster relief of motor symptoms like tremor, slowness, and stiffness than usual clinician-led programming. Using the Medtronic Percept DBS, the study compares standard clinician programming to two signal-guided methods, one that sets stimulation where beta-band power is highest and one that uses broader electrophysiology patterns, with the goal of reducing abnormal brain oscillations while patients continue their regular medications. Adults 21 to 89 with idiopathic Parkinson’s who already have a Percept DBS implanted and can consent at their initial programming session are eligible; people with atypical parkinsonism or who cannot follow the protocol are excluded.
- Who can participate?
- Participants must be between 21 Years and 89 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year.